|
When Dr. Ryan Moy first received a $100,000 seed grant from Gastric Cancer Foundation in 2023, his goal was to investigate the potential of a novel cell therapy targeting CLDN18.2, a protein that’s expressed at high levels in about one-third of gastric cancers. But the company that had planned to provide the cells Moy and his research colleagues needed to do the study was unable to fulfill its commitment, so they revised their plan.
They decided instead to investigate a pathway called YAP/TEAD, which is known to drive the growth of gastric cancer cells. They wanted to determine whether targeting both YAP/TEAD and CLDN18.2 could improve upon therapies that target CLDN18.2 alone.
|